-
In this issue: Statins and diabetes risk; new treatment guideline for diabetes; new pertussis vaccine recommendation; antibiotics and rhinosinusitis; fluoroquinolones and cystitis; and FDA actions.
-
A retrospective review of pediatric cases of dengue fever was undertaken at a single health center in the Bronx area of New York. Over a 3 ½ year period, eight children with dengue infection were identified.
-
In May 2011, an 8-year-old girl developed sore throat, vomiting, and swallowing difficulties. During two emergency room visits with diffuse abdominal pain, she was given intravenous fluids and diagnosed with a viral illness.
-
Case Summary: A 27- year-old physical education teacher presented with two separate episodes of ill-defined dizziness and mild confusion over a period of one week.
-
Timely recognition and treatment of myocardial infarction (MI) are crucial if we are to achieve optimal outcomes for our patients. Silent ischemia, or the absence of classical symptoms of ischemia, may delay the diagnosis.
-
The FDA has approved a second oral drug for the treatment of multiple sclerosis (MS). Teriflunomide, a metabolite of leflunomide and a pyrimidine synthesis inhibitor, is an immunomodulatory agent. It is marketed by Sanofi Aventis as Aubagio.
-
-
Several commonly used photosensitizing antihypertensive drugs can confer as much as a four-fold increase in the risk of lip cancer when prescribed long-term in non-Hispanic whites.
-
This paper updates the American Headache Society and American Academy of Neurology guidelines for prevention of episodic migraine that were previously published in 2000.
-
Results of this year-long intervention trial suggest that an ethanolic extract of curcumin could, together with appropriate dietary and lifestyle changes, play a role in slowing the progression from prediabetes to type 2 diabetes.